HCA
CRSP icon

Heck Capital Advisors’s CRISPR Therapeutics CRSP Stock Holding History

Heck Capital Advisors’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-9
Closed -$354 – 361
2024
Q4 		$354 Buy
+9
New +$425 ﹤0.01% 766

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Heck Capital Advisors's CRSP Position: Q1 2025 in Review

Heck Capital Advisors sold out of CRISPR Therapeutics (CRSP) in Q1 2025, closing a stake of 9 shares — an estimated $354 sold.

Heck Capital Advisors first reported a position in CRSP in Q4 2024 and held it in 1 quarter. The position peaked at $354 in Q4 2024. 396 funds tracked by Wall St. Rank hold CRSP as of Q1 2025.

  • Heck Capital Advisors reported no remaining CRISPR Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Heck Capital Advisors sold 9 CRISPR Therapeutics shares in Q1 2025, an estimated $354.
  • Heck Capital Advisors first reported a position in CRISPR Therapeutics in Q4 2024 and held it in 1 quarter.
  • Heck Capital Advisors's CRISPR Therapeutics position peaked at $354 in Q4 2024.
  • 396 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2025.

Based on Heck Capital Advisors's 13F filing for Q1 2025, filed 13 May 2025.